Sales growth driven by continued strong performance from Kisqali (+64% cc), Entresto (+22% cc), Kesimpta (+33% cc), Scemblix (+79% cc), Leqvio (+61% cc) and Pluvicto (+30% cc) Core operating income ...

Kepler Capital analyst David Evans maintained a Buy rating on Novartis AG on July 14 and set a price target of CHF106.00. The company’s shares closed yesterday at CHF96.06. Elev ...